去甲肾上腺素与特利加压素对ARDS合并脓毒性休克患者效果的比较:一项前瞻性单盲随机对照试验
该前瞻性单盲随机对照试验纳入江西省人民医院重症医学科2015年1月1日至2016年5月1日收治的57例ARDS合并脓毒性休克患者(NE组26例,TP组31例),比较去甲肾上腺素与特利加压素对血流动力学、容量反应性、液体平衡、肾功能及预后的影响。结果显示TP组48小时和72小时心率较NE组显著减慢,72小时中心静脉压显著降低,48小时和72小时容量反应性阳性率显著升高,第2天尿量显著增多且液体平衡显著更负;但两组机械通气时间、ICU住院时间、总住院时间及28天死亡率均无统计学显著差异。
要点
- TP组48小时和72小时心率较NE组显著减慢(82.1±6.8 vs. 87.6±7.4 bpm,81.3±6.1 vs. 85.6±8.3 bpm,均P<0.05)。
- TP组48小时和72小时容量反应性阳性率显著高于NE组(74.2% vs. 46.2%,64.5% vs. 38.5%,均P<0.05)。
- TP组第2天尿量显著多于NE组(2342.8±704.1 vs. 1944.6±684.3 mL/24 h),液体平衡显著更负(-319.7±54.8 vs. -169.6±27.2 mL,均P<0.05)。
- 两组28天死亡率无显著差异(29.0% vs. 30.8%,P>0.05),机械通气时间、ICU住院时间和总住院时间亦无显著差异。
- TP组72小时中心静脉压显著低于NE组(9.4±2.6 vs. 10.9±3.0 mmHg,P<0.05),其余时间点血流动力学指标无显著差异。
适用人群与场景
- 江西省人民医院重症医学科2015年1月1日至2016年5月1日收治的ARDS合并脓毒性休克患者。
- 纳入标准:符合ARDS柏林诊断标准,年龄超过15岁,液体复苏后仍需使用血管升压药。
诊断标准与关键阈值
- ARDS诊断采用柏林诊断标准。
- 容量反应性评估采用被动抬腿试验,以心脏指数变化ΔCI≥10%为容量反应性阳性。
- 目标平均动脉压维持在65-75 mmHg(1 mmHg=0.133 kPa)。
处置流程与药物剂量
- TP组经静脉泵给予特利加压素0.01-0.04 U/min。
- NE组经静脉泵给予去甲肾上腺素>1 μg/min。
- 两组均以平均动脉压65-75 mmHg为目标。
- 采用脉搏指示连续心排血量(PiCCO)监测血流动力学和血管外肺水指数。
研究设计与关键结果
- 研究类型:前瞻性单盲随机对照试验;样本量57例(NE组26例,TP组31例);单中心;人群为ARDS合并脓毒性休克患者。
- 干预与对照:TP组给予特利加压素0.01-0.04 U/min静脉泵入,NE组给予去甲肾上腺素>1 μg/min静脉泵入,目标MAP 65-75 mmHg。
- 主要终点结果:TP组48小时和72小时心率较NE组显著减慢(82.1±6.8 vs. 87.6±7.4 bpm,81.3±6.1 vs. 85.6±8.3 bpm,均P<0.05);72小时中心静脉压显著降低(9.4±2.6 vs. 10.9±3.0 mmHg,P<0.05);其余时间点HR、MAP、CVP、CI、EVLWI、OI和LCR两组无显著差异。
- 关键次要终点:TP组48小时和72小时容量反应性阳性率显著高于NE组(74.2% vs. 46.2%,64.5% vs. 38.5%,均P<0.05);TP组第2天尿量显著增多(2342.8±704.1 vs. 1944.6±684.3 mL/24 h),液体平衡显著更负(-319.7±54.8 vs. -169.6±27.2 mL,均P<0.05);其余时间点容量反应性阳性率、尿量、液体平衡及血清肌酐水平两组无显著差异。
- 不良事件与预后:两组机械通气时间(8.41±2.97 vs. 9.67±3.56天)、ICU住院时间(12.84±4.47 vs. 14.77±5.01天)、总住院时间(19.34±7.37 vs. 21.07±8.41天)及28天死亡率(29.0% vs. 30.8%)均无统计学显著差异(均P>0.05)。
证据类型、等级与局限
- 证据类型:前瞻性单盲随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与去甲肾上腺素相比,特利加压素用于ARDS合并脓毒性休克患者更有利于限制液体负荷、改善肾灌注和增加尿量。
- 两组在稳定血流动力学、缩短机械通气时间、减少ICU或住院天数及降低28天死亡率方面无显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To approach the effect of different vasopressor on hemodynamics, volume responsiveness, fluid volume balance, renal function and prognosis in patients with acute respiratory distress syndrome (ARDS) complicated with septic shock.
METHODS: A prospective single-blind randomized controlled trial was conducted. ARDS patients with septic shock admitted to the Department of Critical Care Medicine of Jiangxi Provincial People's Hospital from January 1st, 2015 to May 1st, 2016 were enrolled. The patients satisfied ARDS Berlin diagnostic criteria, over 15 years old, needing vasopressor after fluid resuscitation were enrolled. The patients were divided into norepinephrine group (NE group) and terlipressin group (TP group) by randomise number table derived by computer. Patients in TP group were given terlipressin (0.01-0.04 U/min) with an intravenous pump, while those of NE group were given norepinephrine (> 1 μg/min) with an intravenous pump, and the target mean arterial pressure (MAP) was maintained at 65-75 mmHg (1 mmHg = 0.133 kPa). Hemodynamics and extravascular lung water index (EVLWI) were monitored by pulse indicator continuous cardiac output (PiCCO). The volume responsiveness of patient was evaluated by passive leg raising (PLR) test, and cardiac index (CI) change (ΔCI ≥ 10%) served as positive volume responsiveness. The differences in hemodynamics, EVLWI, oxygenation index (OI), lactate clearance rate (LCR), rate of positive volume responsiveness, urinary output, fluid volume balance, renal function, and prognostic indicators were compared between the two groups.
RESULTS: Fifty-seven patients with ARDS complicated with septic shock were enrolled, with 26 patients in NE group, and 31 patients in TP group, the baseline data in both groups was balanced with comparability. Compare with NE group, 48-hour and 72-hour heart rate (HR) in TP group was significantly slowed (bpm: 82.1±6.8 vs. 87.6±7.4, 81.3±6.1 vs. 85.6±8.3, both P < 0.05), 72-hour central venous pressure (CVP) was significantly decreased (mmHg: 9.4±2.6 vs. 10.9±3.0, P < 0.05), but no significant difference was found in HR, MAP, CVP, CI, EVLWI, OI and LCR at other time points between the two groups. 48-hour and 72-hour positive volume responsiveness rate in TP group were significantly increased as compared with those of NE group (74.2% vs. 46.2%, 64.5% vs. 38.5%, both P < 0.05), urinary output on the 2nd day (mL/24 h: 2 342.8±704.1 vs. 1 944.6±684.3) and fluid volume balance (mL: -319.7±54.8 vs. -169.6±27.2) were significantly decreased (both P < 0.05). There was no significant difference in positive volume responsiveness rate, urine output, fluid volume balance, and the level of serum creatinine at other time points between the two groups. There was no statistically significant difference in the following features between TP group and NE group: duration of mechanical ventilation (days: 8.41±2.97 vs. 9.67±3.56), length of intensive care unit (ICU) stay (days: 12.84±4.47 vs. 14.77±5.01), total length of hospital stay (days: 19.34±7.37 vs. 21.07±8.41), and 28-day mortality (29.0% vs. 30.8%, all P > 0.05).
CONCLUSIONS: Compared with norepinephrine, terlipressin for ARDS patients with septic shock is more conducive to restrict fluid load, improve the renal perfusion and increase urine output. However, in both groups there was no significant difference in the efficiency of stabilizing hemodynamics, shortening the duration of mechanical ventilation, reducing ICU or hospital days and decreasing 28-day mortality.
参考来源
- Chen Z, Zhou P, Lu Y, et al. [Comparison of effect of norepinephrine and terlipressin on patients with ARDS combined with septic shock: a prospective single-blind randomized controlled trial]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 28625256. doi:10.3760/cma.j.issn.2095-4352.2017.02.004
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。